Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 2
2001 1
2002 2
2003 1
2005 1
2006 2
2007 1
2008 2
2009 2
2011 3
2012 1
2013 1
2014 1
2015 2
2016 1
2017 2
2020 1
2021 1
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Foreword.
Ryan C, Burcombe R, Coleby T. Ryan C, et al. Among authors: burcombe r. Br J Nurs. 2017 Sep 5;26(Sup16a):S3. doi: 10.12968/bjon.2017.26.Sup16a.S3. Br J Nurs. 2017. PMID: 28981332
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Davies C, et al. Lancet. 2013 Mar 9;381(9869):805-16. doi: 10.1016/S0140-6736(12)61963-1. Lancet. 2013. PMID: 23219286 Free PMC article. Clinical Trial.
Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010).
Ring A, Kilburn LS, Pearson A, Moretti L, Afshari-Mehr A, Wardley AM, Gurel B, Macpherson IR, Riisnaes R, Baird RD, Martin S, Roylance R, Johnson H, Ferreira A, Winter MC, Dunne K, Copson E, Hickish T, Burcombe R, Randle K, Serra V, Llop-Guevara A, Bliss JM, Turner NC. Ring A, et al. Among authors: burcombe r. Clin Cancer Res. 2023 Dec 1;29(23):4751-4759. doi: 10.1158/1078-0432.CCR-23-1696. Clin Cancer Res. 2023. PMID: 37773077 Free PMC article. Clinical Trial.
Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer.
Regan MM, Price KN, Giobbie-Hurder A, Thürlimann B, Gelber RD; International Breast Cancer Study Group and BIG 1-98 Collaborative Group. Regan MM, et al. Breast Cancer Res. 2011 May 26;13(3):209. doi: 10.1186/bcr2837. Breast Cancer Res. 2011. PMID: 21635709 Free PMC article. Review.
HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer.
Bergamino MA, López-Knowles E, Morani G, Tovey H, Kilburn L, Schuster EF, Alataki A, Hills M, Xiao H, Holcombe C, Skene A, Robertson JF, Smith IE, Bliss JM, Dowsett M, Cheang MCU; POETIC investigators. Bergamino MA, et al. EBioMedicine. 2022 Sep;83:104205. doi: 10.1016/j.ebiom.2022.104205. Epub 2022 Aug 16. EBioMedicine. 2022. PMID: 35985932 Free PMC article.
Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation.
Gellert P, Segal CV, Gao Q, López-Knowles E, Martin LA, Dodson A, Li T, Miller CA, Lu C, Mardis ER, Gillman A, Morden J, Graf M, Sidhu K, Evans A, Shere M, Holcombe C, McIntosh SA, Bundred N, Skene A, Maxwell W, Robertson J, Bliss JM, Smith I, Dowsett M; POETIC Trial Management Group and Trialists. Gellert P, et al. Nat Commun. 2016 Nov 9;7:13294. doi: 10.1038/ncomms13294. Nat Commun. 2016. PMID: 27827358 Free PMC article. Clinical Trial.
Hyperhomocysteinemia in women with advanced breast cancer.
Gatt A, Makris A, Cladd H, Burcombe RJ, Smith JM, Cooper P, Thompson D, Makris M. Gatt A, et al. Among authors: burcombe rj. Int J Lab Hematol. 2007 Dec;29(6):421-5. doi: 10.1111/j.1751-553X.2007.00907.x. Int J Lab Hematol. 2007. PMID: 17988296
Enhanced axillary assessment using intradermally injected microbubbles and contrast-enhanced ultrasound (CEUS) before neoadjuvant systemic therapy (NACT) identifies axillary disease missed by conventional B-mode ultrasound that may be clinically relevant.
Cox K, Dineen N, Taylor-Phillips S, Sharma N, Harper-Wynne C, Allen D, Weeks J, Chalmers R, Akolekar D, Burcombe R, Jyothirmayi R, Sever A. Cox K, et al. Among authors: burcombe r. Breast Cancer Res Treat. 2021 Jan;185(2):413-422. doi: 10.1007/s10549-020-05956-0. Epub 2020 Oct 7. Breast Cancer Res Treat. 2021. PMID: 33029707
28 results